Posted by Michael Wonder on 15 Feb 2020
FDA approves Agile Therapeutics' Twirla (levonorgestrel and ethinyl estradiol) transdermal system – a new weekly contraceptive patch delivering a 30 mcg daily dose of oestrogen and 120 mcg daily dose of progestin
14 February 2020 - Twirla is a new non-daily, non-invasive contraceptive approved in the U.S.
Agile Therapeutics today announced that the U.S. FDA has approved Twirla (levonorgestrel and ethinyl estradiol) transdermal system.
Twirla is indicated as a method of contraception for use in women of reproductive potential with a BMI < 30 kg/m2 for whom a combined hormonal contraceptive is appropriate.
